Day One Biopharmaceuticals is highlighted as a top buyout candidate due to its focus on pediatric cancer treatments and a promising drug pipeline. The company's strong financial position, with $558.4M in cash and a cash runway of over 3 years, reduces dilution risk. Wall Street's target of a 190% stock increase suggests significant upside potential, making it an attractive investment opportunity.